In addition, crizotinib, which is a small molecule inhibitor of c-MET—approved for the treatment of ALK-positive NSCLC by the FDA, has been shown to be effective in the treatment of a subset of patients with c-MET-amplified gastric or esophageal tumors [47]. This evidence concerns the gene MET and non-small cell lung carcinoma.